{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T01:00:42Z","timestamp":1790470842941,"version":"4.1.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T00:00:00Z","timestamp":1686614400000},"content-version":"vor","delay-in-days":12,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"publisher","award":["2022JJ40849"],"award-info":[{"award-number":["2022JJ40849"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011790","name":"Xiangya Hospital, Central South University","doi-asserted-by":"publisher","award":["2021Q20"],"award-info":[{"award-number":["2021Q20"]}],"id":[{"id":"10.13039\/501100011790","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.heliyon.2023.e17295","type":"journal-article","created":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T23:26:22Z","timestamp":1686871582000},"page":"e17295","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Inhibition of stress proteins TRIB3 and STC2 potentiates sorafenib sensitivity in hepatocellular carcinoma"],"prefix":"10.1016","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8896-1006","authenticated-orcid":false,"given":"Sheng","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huanji","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianhong","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2021","key":"10.1016\/j.heliyon.2023.e17295_bib1","first-page":"209","article-title":"GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2020","journal-title":"Ca - Cancer J. Clin."},{"key":"10.1016\/j.heliyon.2023.e17295_bib2","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41575-019-0186-y","article-title":"A global view of hepatocellular carcinoma: trends, risk, prevention and management","volume":"16","author":"Yang","year":"2019","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.heliyon.2023.e17295_bib3","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/s41571-018-0073-4","article-title":"Molecular therapies and precision medicine for hepatocellular carcinoma","volume":"15","author":"Llovet","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.heliyon.2023.e17295_bib4","doi-asserted-by":"crossref","first-page":"256","DOI":"10.21037\/jgo.2016.09.07","article-title":"Hepatocellular carcinoma (HCC): beyond sorafenib-chemotherapy","volume":"8","author":"Kim","year":"2017","journal-title":"J. Gastrointest. Oncol."},{"key":"10.1016\/j.heliyon.2023.e17295_bib5","doi-asserted-by":"crossref","DOI":"10.3390\/cancers10110412","article-title":"Systemic therapy for hepatocellular carcinoma: latest advances","volume":"10","author":"Kudo","year":"2018","journal-title":"Cancers"},{"key":"10.1016\/j.heliyon.2023.e17295_bib6","first-page":"525","article-title":"Advances in immunotherapy for hepatocellular carcinoma, Nature reviews","volume":"18","author":"Sangro","year":"2021","journal-title":"Gastroenterol. Hepatol."},{"key":"10.1016\/j.heliyon.2023.e17295_bib7","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/aps.2017.5","article-title":"New knowledge of the mechanisms of sorafenib resistance in liver cancer","volume":"38","author":"Zhu","year":"2017","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.heliyon.2023.e17295_bib8","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1080\/02656730701858305","article-title":"Heat shock proteins: stress proteins with Janus-like properties in cancer","volume":"24","author":"Calderwood","year":"2008","journal-title":"Int. J. Hyperther. : Off. J. Eur. Soc. Hyperthermic Oncol."},{"key":"10.1016\/j.heliyon.2023.e17295_bib9","doi-asserted-by":"crossref","first-page":"252","DOI":"10.2174\/138920207781386951","article-title":"The role of stress proteins in prostate cancer","volume":"8","author":"So","year":"2007","journal-title":"Curr. Genom."},{"key":"10.1016\/j.heliyon.2023.e17295_bib10","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/nrd2130","article-title":"Discovery and development of sorafenib: a multikinase inhibitor for treating cancer, Nature reviews","volume":"5","author":"Wilhelm","year":"2006","journal-title":"Drug Discov."},{"key":"10.1016\/j.heliyon.2023.e17295_bib11","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1634\/theoncologist.2008-0185","article-title":"Sorafenib for the treatment of unresectable hepatocellular carcinoma","volume":"14","author":"Kane","year":"2009","journal-title":"Oncol."},{"key":"10.1016\/j.heliyon.2023.e17295_bib12","doi-asserted-by":"crossref","first-page":"741","DOI":"10.2147\/JHC.S285726","article-title":"Elucidating the molecular basis of sorafenib resistance in HCC: current findings and future directions","volume":"8","author":"Fornari","year":"2021","journal-title":"J. Hepatocell. Carcinoma"},{"key":"10.1016\/j.heliyon.2023.e17295_bib13","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/s41392-020-0187-x","article-title":"The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects","volume":"5","author":"Tang","year":"2020","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.heliyon.2023.e17295_bib14","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.jhep.2012.02.019","article-title":"Epidermal growth factor receptor and HER-3 restrict cell response to sorafenib in hepatocellular carcinoma cells","volume":"57","author":"Blivet-Van Eggelpo\u00ebl","year":"2012","journal-title":"J. Hepatol."},{"key":"10.1016\/j.heliyon.2023.e17295_bib15","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1002\/ijc.27604","article-title":"EGFR activation is a potential determinant of primary resistance of hepatocellular carcinoma cells to sorafenib","volume":"131","author":"Ezzoukhry","year":"2012","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.heliyon.2023.e17295_bib16","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/1741-7015-7-41","article-title":"Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: evidence from an in vitro study","volume":"7","author":"Zhang","year":"2009","journal-title":"BMC Med."},{"key":"10.1016\/j.heliyon.2023.e17295_bib17","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1038\/bjc.2012.145","article-title":"Activation of JNK and high expression level of CD133 predict a poor response to sorafenib in hepatocellular carcinoma","volume":"106","author":"Hagiwara","year":"2012","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.heliyon.2023.e17295_bib18","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.ccr.2014.04.019","article-title":"Focal gains of VEGFA: candidate predictors of sorafenib response in hepatocellular carcinoma","volume":"25","author":"Llovet","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.heliyon.2023.e17295_bib19","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.ejmech.2012.07.023","article-title":"Blockade of STAT3 activation by sorafenib derivatives through enhancing SHP-1 phosphatase activity","volume":"55","author":"Chen","year":"2012","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.heliyon.2023.e17295_bib20","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/ijc.26374","article-title":"Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma","volume":"131","author":"Shimizu","year":"2012","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.heliyon.2023.e17295_bib21","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1097\/CAD.0000000000001329","article-title":"KDM5B regulates the PTEN\/PI3K\/Akt pathway to increase sorafenib-resistance in hepatocellular carcinoma","volume":"33","author":"Liu","year":"2022","journal-title":"Anti Cancer Drugs"},{"key":"10.1016\/j.heliyon.2023.e17295_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106244","article-title":"Epigenetic regulation of the DNMT1\/MT1G\/KLF4\/CA9 axis synergises the anticancer effects of sorafenib in hepatocellular carcinoma","volume":"180","author":"Wei","year":"2022","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.heliyon.2023.e17295_bib23","article-title":"DJ-1\/FGFR-1 signaling pathway contributes to sorafenib resistance in hepatocellular carcinoma","volume":"2022","author":"Chen","year":"2022","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.heliyon.2023.e17295_bib24","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13081822","article-title":"Tribbles Pseudokinase 3 regulation and contribution to cancer","volume":"13","author":"Stefanovska","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.heliyon.2023.e17295_bib25","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/s13046-022-02370-w","article-title":"Stanniocalcin 2 (STC2): a universal tumour biomarker and a potential therapeutical target","volume":"41","author":"Qie","year":"2022","journal-title":"J. Exp. Clin. Cancer Res. : CRN"},{"key":"10.1016\/j.heliyon.2023.e17295_bib26","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1038\/sj.emboj.7600596","article-title":"TRB3, a novel ER stress-inducible gene, is induced via ATF4-CHOP pathway and is involved in cell death","volume":"24","author":"Ohoka","year":"2005","journal-title":"EMBO J."},{"key":"10.1016\/j.heliyon.2023.e17295_bib27","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.bbrc.2005.02.149","article-title":"Characterization of human NIPK (TRB3, SKIP3) gene activation in stressful conditions","volume":"330","author":"Ord","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.heliyon.2023.e17295_bib28","doi-asserted-by":"crossref","first-page":"15851","DOI":"10.1074\/jbc.M611723200","article-title":"TRB3 inhibits the transcriptional activation of stress-regulated genes by a negative feedback on the ATF4 pathway","volume":"282","author":"Jousse","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.heliyon.2023.e17295_bib29","first-page":"E565","article-title":"Mammalian Tribbles homolog 3 impairs insulin action in skeletal muscle: role in glucose-induced insulin resistance, American journal of physiology","volume":"298","author":"Liu","year":"2010","journal-title":"Endocrinol. Metabol."},{"key":"10.1016\/j.heliyon.2023.e17295_bib30","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1016\/j.bbamcr.2015.06.006","article-title":"TRIB3 enhances cell viability during glucose deprivation in HEK293-derived cells by upregulating IGFBP2, a novel nutrient deficiency survival factor","volume":"1853","author":"\u00d6rd","year":"2015","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.heliyon.2023.e17295_bib31","doi-asserted-by":"crossref","first-page":"3556","DOI":"10.1016\/j.yexcr.2007.07.017","article-title":"TRB3 protects cells against the growth inhibitory and cytotoxic effect of ATF4","volume":"313","author":"Ord","year":"2007","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.heliyon.2023.e17295_bib32","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1053\/j.gastro.2018.10.031","article-title":"TRIB3 interacts with \u03b2-catenin and TCF4 to increase stem cell features of colorectal cancer stem cells and tumorigenesis","volume":"156","author":"Hua","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.heliyon.2023.e17295_bib33","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1073\/pnas.1214014110","article-title":"High throughput kinase inhibitor screens reveal TRB3 and MAPK-ERK\/TGF\u03b2 pathways as fundamental Notch regulators in breast cancer","volume":"110","author":"Izrailit","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.heliyon.2023.e17295_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.118021","article-title":"TRIB3 destabilizes tumor suppressor PPAR\u03b1 expression through ubiquitin-mediated proteasome degradation in acute myeloid leukemia","volume":"257","author":"Luo","year":"2020","journal-title":"Life Sci."},{"key":"10.1016\/j.heliyon.2023.e17295_bib35","doi-asserted-by":"crossref","first-page":"7276","DOI":"10.1080\/21655979.2021.1977551","article-title":"The significance of Stanniocalcin 2 in malignancies and mechanisms","volume":"12","author":"Li","year":"2021","journal-title":"Bioengineered"},{"key":"10.1016\/j.heliyon.2023.e17295_bib36","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1016\/j.yexcr.2008.03.001","article-title":"Wong, Epigenetic and HIF-1 regulation of stanniocalcin-2 expression in human cancer cells","volume":"314","author":"Law","year":"2008","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.heliyon.2023.e17295_bib37","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1016\/j.yexcr.2010.06.026","article-title":"Stanniocalcin-2 promotes epithelial-mesenchymal transition and invasiveness in hypoxic human ovarian cancer cells","volume":"316","author":"Law","year":"2010","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.heliyon.2023.e17295_bib38","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1002\/ijc.32487","article-title":"Acquired resistance to EGFR tyrosine kinase inhibitors is mediated by the reactivation of STC2\/JUN\/AXL signaling in lung cancer","volume":"145","author":"Liu","year":"2019","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.heliyon.2023.e17295_bib39","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1002\/ijc.24564","article-title":"Stanniocalcin 2 promotes invasion and is associated with metastatic stages in neuroblastoma","volume":"125","author":"Volland","year":"2009","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.heliyon.2023.e17295_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.109581","article-title":"The functions and molecular mechanisms of Tribbles homolog 3 (TRIB3) implicated in the pathophysiology of cancer","volume":"114","author":"Arif","year":"2023","journal-title":"Int. Immunopharm."},{"key":"10.1016\/j.heliyon.2023.e17295_bib41","first-page":"1343","article-title":"TRB3 reverses chemotherapy resistance and mediates crosstalk between endoplasmic reticulum stress and AKT signaling pathways in MHCC97H human hepatocellular carcinoma cells","volume":"15","author":"Li","year":"2018","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.heliyon.2023.e17295_bib42","first-page":"210","article-title":"Overcoming STC2 mediated drug resistance through drug and gene co-delivery by PHB-PDMAEMA cationic polyester in liver cancer cells, Materials science & engineering","volume":"83","author":"Cheng","year":"2018","journal-title":"C Mater. Biol. Appl."},{"key":"10.1016\/j.heliyon.2023.e17295_bib43","doi-asserted-by":"crossref","first-page":"3660","DOI":"10.1038\/s41467-020-17385-0","article-title":"TRIB3-EGFR interaction promotes lung cancer progression and defines a therapeutic target","volume":"11","author":"Yu","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.heliyon.2023.e17295_bib44","article-title":"Epithelial-mesenchymal transition-mediated tumor therapeutic resistance","volume":"27","author":"Xu","year":"2022","journal-title":"Molecules"}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844023045036?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844023045036?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T00:34:03Z","timestamp":1790469243000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844023045036"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":44,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S2405844023045036"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2023.e17295","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhibition of stress proteins TRIB3 and STC2 potentiates sorafenib sensitivity in hepatocellular carcinoma","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2023.e17295","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e17295"}}